DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population

Inclusion Criteria: * Minimum age of 18 years; * Coronary artery disease and lesion(s) eligible for treatment with drug eluting stents according to clinical guidelines and/or the operators' judgement; * Patient is willing and able to cooperate with study procedures and required follow-up visits; and patient has been informed and agrees on the participation by signing an EC approved written informed consent. Exclusion Criteria: * Participation in another randomized drug or device study before reaching primary endpoint; * Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained throughout the peri-surgical period; * Intolerance to a P2Y12 receptor antagonist that results in the patient's inability to adhere to dual-antiplatelet therapy, or intolerance to aspirin, heparin, or components of the two DES examined; * Known pregnancy; * Life expectancy of less than 1 year.